How Does Matthews International Corporation (NASDAQ:MATW) Affect Your Portfolio Volatility?
Anonymousronwdavis.com
LONDON, May 2 (Reuters) - AstraZenecas board will be reviewing a sweetened takeover offer from Pfizer but the company has no further comment at this stage, a spokeswoman for the British drugmaker said on Friday. Earlier the U.S. drugmaker revealed it had raised its offer for the British group to 63 billion pounds ($106 billion). (Reporting by Ben Hirschler; editing by Kate Holton) View comments
Embracing the Chaotic Morning Routine for a Fulfilling Day
Discover how a messy morning routine can lead to greater happiness and productivity in your daily life.